Literature DB >> 32156781

BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1.

Dan Zong1,2, Jiajia Gu1,2, Giovanna C Cavalcante2,3, Weilong Yao2,4, Guojing Zhang2, Shaomeng Wang5, Taofeek K Owonikoko2, Xia He6, Shi-Yong Sun7.   

Abstract

Lung cancer consists of approximately 80% non-small cell lung cancer (NSCLC) and 20% small cell lung cancer (SCLC) and remains the leading cause of cancer-related deaths worldwide despite advances in early diagnosis, targeted therapy, and immunotherapy. Thus, novel therapies are still urgently needed. Bromodomain and extraterminal (BET) proteins, primarily comprised of BRD2, BRD3, and BRD4 proteins, function as epigenetic readers and master transcription coactivators and are now recognized cancer therapeutic targets. BET degraders such as ZBC260 and dBET represent a novel class of BET inhibitors that act by inducing BET degradation. The current study demonstrates the therapeutic efficacies of BET degraders, particularly ZBC260, against lung cancer, as well as understanding the underlying mechanisms and identifying molecular markers that determine cell sensitivity to BET degraders. A panel of NSCLC cell lines possessed similar response patterns to ZBC260 and dBET but different responses to BET inhibitor JQ-1. BRD levels, particularly BRD4, correlated positively with high sensitivity to BET degraders but not to JQ-1. BET degraders potently induced apoptosis in sensitive NSCLC cells and were accompanied by reduction of Mcl-1 and c-FLIP levels, which are critical for mediating induction of apoptosis and enhancement of TRAIL-induced apoptosis. Accordingly, ZBC260 exerted more potent activity than JQ-1 in vivo against the growth of NSCLC xenografts and patient-derived xenografts. These findings warrant future clinical validation of the efficacy of BET degraders in NSCLC, particularly those with high levels of BRD proteins, especially BRD4. SIGNIFICANCE: The current study demonstrates the potential of novel BET degraders in the treatment of lung cancer and warrants clinical validation of BET degraders in lung cancer with high levels of BRD4. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32156781     DOI: 10.1158/0008-5472.CAN-19-3674

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.

Authors:  Chaoyuan Liu; Luxi Qian; Karin A Vallega; Guangzhi Ma; Dan Zong; Luxiao Chen; Shaomeng Wang; Suresh R Ramalingam; Zhaohui Qin; Shi-Yong Sun
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

2.  A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization.

Authors:  Tingting Yang; Yuzhu Hu; Junming Miao; Jing Chen; Jiagang Liu; Yongzhong Cheng; Xiang Gao
Journal:  Acta Pharm Sin B       Date:  2022-02-16       Impact factor: 14.903

3.  Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader.

Authors:  Anand Divakaran; Cole R Scholtz; Huda Zahid; Wenwei Lin; Elizabeth C Griffith; Richard E Lee; Taosheng Chen; Daniel A Harki; William C K Pomerantz
Journal:  ACS Med Chem Lett       Date:  2022-09-29       Impact factor: 4.632

4.  BRD4 inhibition promotes TRAIL-induced apoptosis by suppressing the transcriptional activity of NF-κB in NSCLC.

Authors:  Liu Shi; Yu Xiong; Xiaoyan Hu; Zhihao Wang; Conghua Xie
Journal:  Int J Med Sci       Date:  2021-06-26       Impact factor: 3.738

5.  Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.

Authors:  Karin Bauer; Anna S Berghoff; Matthias Preusser; Gerwin Heller; Christoph C Zielinski; Peter Valent; Thomas W Grunt
Journal:  Am J Cancer Res       Date:  2021-02-01       Impact factor: 6.166

6.  Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma.

Authors:  Yuting Meng; Xixi Qian; Li Zhao; Nan Li; Shengjie Wu; Baoan Chen; Tong Sun; Xuerong Wang
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

7.  Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles.

Authors:  Yihong He; Xin Zan; Junming Miao; Bilan Wang; Yin Wu; Yangmei Shen; Xinchuan Chen; Hongfeng Gou; Songping Zheng; Ning Huang; Yongzhong Cheng; Yan Ju; Xianghui Fu; Zhiyong Qian; Peizhi Zhou; Jiagang Liu; Xiang Gao
Journal:  Mater Today Bio       Date:  2022-09-12

8.  Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.

Authors:  Huan-Tian Zhang; Rui Peng; Sheng Chen; Ao Shen; Lixin Zhao; Wang Tang; Xiao-He Wang; Zhen-Yan Li; Zhen-Gang Zha; Mengmeng Yi; Lingmin Zhang
Journal:  Adv Sci (Weinh)       Date:  2022-08-21       Impact factor: 17.521

9.  Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.

Authors:  Lei Zhu; Zhen Chen; Hongjing Zang; Songqing Fan; Jiajia Gu; Guojing Zhang; Kevin D-Y Sun; Qiming Wang; Yong He; Taofeek K Owonikoko; Suresh S Ramalingam; Shi-Yong Sun
Journal:  Cancer Res       Date:  2021-07-21       Impact factor: 12.701

10.  Impact of bromodomain-containing protein 4 (BRD4) and intestine-specific homeobox (ISX) expression on the prognosis of patients with hepatocellular carcinoma' for better clarity.

Authors:  Kai-Ting Chuang; Shen-Nien Wang; Shih-Hsien Hsu; Li-Ting Wang
Journal:  Cancer Med       Date:  2021-06-25       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.